Viridian Therapeutics (VRDN) delivered a double dose of news that is catching investors’ attention. The company posted a dramatic jump in third quarter revenue and a much smaller net loss, while also submitting its BLA for veligrotug to the FDA.

Viridian Therapeutics has been shaping up as one of the year’s standout movers, with its share price up 67% over the past three months and nearly 29% for the month. This performance has been fueled by breakthrough clinical milestones and record quarterly results. The stock’s recent momentum suggests investors are increasingly optimistic about its pipeline and path to profitability, even when considering only a modest total shareholder return of 9% over the past year amid some ups and downs along the way.

If Viridian’s story has you interested in where biotech innovation is headed, it’s an ideal time to explore See the full list for free..

This remarkable run raises a key question for investors: Is Viridian still undervalued given its accelerating momentum, or has the market already accounted for all the future growth in its soaring share price?

Price-to-Sales of 37x: Is it justified?

Viridian Therapeutics currently trades at a price-to-sales ratio of 37x, which signals a significant premium compared to peers and industry norms, especially given a last close price of $27.44.

The price-to-sales (P/S) metric compares a company’s market capitalization to its total sales. This metric is a popular tool for evaluating biotechs that may not yet be profitable. A higher P/S ratio indicates that investors are paying more per dollar of revenue and can often reflect high expectations of future growth or breakthrough potential.

Viridian’s 37x multiple is steep relative to the US Biotechs industry average of 11.2x and the peer average of 16.4x. This suggests the stock is richly valued based on sales alone. Additionally, the company trades at 89.8% above its estimated fair P/S ratio of 0.1x, which could indicate that market enthusiasm is getting ahead of fundamentals.

Result: Price-to-Sales of 37x (OVERVALUED)

However, investors should keep in mind that limited profitability and reliance on continued revenue growth remain key uncertainties that could impact future returns.

Another View: What Does the SWS DCF Model Say?

While sales-based multiples make Viridian Therapeutics look expensive, our SWS DCF model presents a very different picture. According to this approach, VRDN shares are actually trading below the estimated fair value. This suggests the market may be undervaluing long-term cash flow potential, even in the face of near-term losses. Could this indicate overlooked upside, or does it highlight the risks associated with forecasting for early-stage biotechs?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Viridian Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 870 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Build Your Own Viridian Therapeutics Narrative

Keep in mind, if you see things differently or want to draw your own conclusions from the data, you can shape your own outlook in just a few minutes using our tools. Do it your way.

A great starting point for your Viridian Therapeutics research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

If you want to stay ahead of the market, now is the perfect time to broaden your search and act on compelling opportunities using the Simply Wall Street Screener.

• Capture major growth potential by reviewing these 24 AI penny stocks shaping tomorrow’s technological landscape and riding the artificial intelligence wave.
• Boost your portfolio’s passive income by identifying these 16 dividend stocks with yields > 3% offering attractive yields above 3% and strong financial fundamentals.
• Get ahead of the next trend by spotting game-changing technologies with these 27 quantum computing stocks for innovation in quantum computing and future-defining breakthroughs.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.